Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Research and Innovation Action · Running

DEFINITIVE Diagnostic HER2DX-guided treatment for patients with early-stage HER2-positive breast cancer

Coordinator
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer, Spain
Runs
1 December 2023 to 30 November 2028
Status
Running
EU funding
€8.0m
Total cost
€8.0m
Partners
19 organisations in 10 countries
Type
Research and Innovation Action
Grant agreement
101136953

What the project is doing

In the project's own words, from its summary on CORDIS.

HER2+ breast cancer affects around 390.000 women annually worldwide (i.e. 3 patients every 4 minutes). Over the last decade, polychemotherapy and HER2-targeted therapies have improved patient´s survival; however, the reality is that most patients are cured with less intense, toxic, and costly drugs. Up to now, no diagnostic test existed to guide the optimal therapy for each patient. The 27-gene HER2DX test (TRL8) is a novel minimally invasive diagnostic tool which provides unprecedented predictive information for therapy optimization in early-stage HER2+ disease.

The DEFINITIVE project will prospectively validate HER2DX`s clinical effectiveness, proving its ability to significantly i) reduce toxicities, ii) improve quality of life and ii) reduce direct and indirect costs, while maintaining efficacy endpoints and survival outcomes in patients with early HER2+ breast cancer. DEFINITIVE will combine international experts in breast cancer from international reference hospitals, comprehensive cancer networks, regulatory, HTA and medical statistics experts, SMEs, policy makers, patient associations, living labs and medical society networks.

DEFINITIVE consortium will conduct a pragmatic clinical trial across 44 centres in 7 European and associated countries to randomize 304 patients with stage II to IIIA HER2+ breast cancer, in a 1:1 manner, and to be treated with the result of the HER2DX test to guide treatment vs without the result of the test (treatment by physician´s choice according to local guidelines). The inclusion and exclusion criteria will be very broad to make sure that most patients can participate in the trial and the results could be generalized to the overall population treated in real-world settings.

Beyond seeking the endorsement and implementation of HER2DX diagnostic test by clinical guidelines and healthcare systems, DEFINITIVE will boost the incorporation of affordable non-invasive diagnostic tools in the field of genomics and precision oncology. This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics)”.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I SunyerBarcelonaSpainCoordinator
Medizinische Universitaet WienWienAustriaParticipant
Verein Zur Pravention Und Therapie Bosartiger Erkrankungen, Austrian Breast and Colorectal Cancer Study Group, AbcsgWienAustriaParticipant
Societe Internationale D Oncologie GeriatriqueLas AcaciasSwitzerlandAssociatedpartner
Sharing Progress in Cancer CareBellinzonaSwitzerlandAssociatedpartner
Wsg Westdeutsche Studiengruppe GmbHMonchengladbachGermanyParticipant
Gr Espanol De Estudio Y Tratamientode Intensific. Y Otras Estrateg.experiment. En Tumores Solidos - Grupo SoltiBarcelonaSpainParticipant
Hospital Clinic De BarcelonaBarcelonaSpainThird party
Institut Catala D'oncologiaHospitalet de LlobregatSpainParticipant
Reveal Genomics SLBarcelonaSpainParticipant
UnicancerParisFranceParticipant
University College Cork - National University of Ireland, CorkCorkIrelandParticipant
Medical Research Infrastructure Development and Health Services Fund by the Sheba Medical CenterRamat GanIsraelParticipant
Europa Donna the European Breast Cancer CoalitionMilanoItalyParticipant
Istituto Europeo Di Oncologia SRLMilanoItalyParticipant
Istituto Oncologico VenetoPadovaItalyThird party
Universita Degli Studi Di PadovaPadovaItalyParticipant
Erasmus Universiteit RotterdamRotterdamNetherlandsParticipant
Europa Donna Slovensko Zdruzenje Za Boj Proti Raku DojkLjubljanaSloveniaThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI